TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial
Abstract Meibomian gland dysfunction (MGD) is the most common cause of dry eye disease (DED). In this study, we aimed to compare the effects of eyelid warming treatment using either TheraPearl Eye Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam (Spectrum Thea Pharmaceuticals LTD, Maccles...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-01899-8 |
| _version_ | 1818988386954772480 |
|---|---|
| author | Jonatan Olafsson Xiaoran Lai Erlend Christoffer Sommer Landsend Snorri Olafsson Eric Parissi Øygunn A. Utheim Sten Raeder Reza A. Badian Neil Lagali Darlene A. Dartt Tor P. Utheim |
| author_facet | Jonatan Olafsson Xiaoran Lai Erlend Christoffer Sommer Landsend Snorri Olafsson Eric Parissi Øygunn A. Utheim Sten Raeder Reza A. Badian Neil Lagali Darlene A. Dartt Tor P. Utheim |
| author_sort | Jonatan Olafsson |
| collection | DOAJ |
| description | Abstract Meibomian gland dysfunction (MGD) is the most common cause of dry eye disease (DED). In this study, we aimed to compare the effects of eyelid warming treatment using either TheraPearl Eye Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK) in a Norwegian population with mild to moderate MGD-related DED. An open label, randomized comparative trial with seventy patients (49 females, 21 males; mean age 53.6 years). Patients were randomly assigned to treatment with Blephasteam (n = 37) or TheraPearl (n = 33). All received a hyaluronic acid based artificial tear substitute (Hylo-Comod, Ursapharm, Saarbrücken, Germany). Patients were examined at baseline, and at three and six months initiation of treatment. Treatment efficacy was primarily evaluated by fluorescein breakup time (FBUT) and Ocular Surface Disease Index (OSDI) scores. Other outcome measures included ocular surface staining (OSS), Schirmer’s test, and meibomian quality and expressibility. Baseline parameter values did not differ between the groups. After six months of treatment, Blephasteam improved FBUT by 3.9 s (p < 0.01) and OSDI by 13.7 (p < 0.01), TheraPearl improved FBUT by 2.6 s (p < 0.01) and OSDI by 12.6 (p < 0.01). No difference between treatments was detected at 6 months (p = 0.11 for FBUT and p = 0.71 for OSDI), nor were there differences in the other tested parameters between the treatment groups. Blephasteam and TheraPearl are equally effective in treating mild to moderate MGD in a Norwegian population after 6-months of treatment. Clinicaltrials.gov ID: NCT03318874; Protocol ID: 2014/1983; First registration: 24/10/2017. |
| first_indexed | 2024-12-20T19:21:46Z |
| format | Article |
| id | doaj.art-899420784eb743f4964bd70d03d513ec |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-20T19:21:46Z |
| publishDate | 2021-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-899420784eb743f4964bd70d03d513ec2022-12-21T19:28:59ZengNature PortfolioScientific Reports2045-23222021-11-0111111010.1038/s41598-021-01899-8TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trialJonatan Olafsson0Xiaoran Lai1Erlend Christoffer Sommer Landsend2Snorri Olafsson3Eric Parissi4Øygunn A. Utheim5Sten Raeder6Reza A. Badian7Neil Lagali8Darlene A. Dartt9Tor P. Utheim10Institute of Clinical Medicine, Faculty of Medicine, University of OsloDepartment of Biostatistics, Institute of Basic Medical Sciences, University of OsloDepartment of Ophthalmology, Oslo University HospitalDepartment of Gastroenterology, Innlandet Hospital TrustLavista OptometryInstitute of Clinical Medicine, Faculty of Medicine, University of OsloInstitute of Clinical Medicine, Faculty of Medicine, University of OsloDepartment of Medical Biochemistry, Oslo University HospitalDivision of Ophthalmology, Department of Biomedical and Clinical Sciences, Linköping UniversityDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical SchoolDepartment of Medical Biochemistry, Oslo University HospitalAbstract Meibomian gland dysfunction (MGD) is the most common cause of dry eye disease (DED). In this study, we aimed to compare the effects of eyelid warming treatment using either TheraPearl Eye Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK) in a Norwegian population with mild to moderate MGD-related DED. An open label, randomized comparative trial with seventy patients (49 females, 21 males; mean age 53.6 years). Patients were randomly assigned to treatment with Blephasteam (n = 37) or TheraPearl (n = 33). All received a hyaluronic acid based artificial tear substitute (Hylo-Comod, Ursapharm, Saarbrücken, Germany). Patients were examined at baseline, and at three and six months initiation of treatment. Treatment efficacy was primarily evaluated by fluorescein breakup time (FBUT) and Ocular Surface Disease Index (OSDI) scores. Other outcome measures included ocular surface staining (OSS), Schirmer’s test, and meibomian quality and expressibility. Baseline parameter values did not differ between the groups. After six months of treatment, Blephasteam improved FBUT by 3.9 s (p < 0.01) and OSDI by 13.7 (p < 0.01), TheraPearl improved FBUT by 2.6 s (p < 0.01) and OSDI by 12.6 (p < 0.01). No difference between treatments was detected at 6 months (p = 0.11 for FBUT and p = 0.71 for OSDI), nor were there differences in the other tested parameters between the treatment groups. Blephasteam and TheraPearl are equally effective in treating mild to moderate MGD in a Norwegian population after 6-months of treatment. Clinicaltrials.gov ID: NCT03318874; Protocol ID: 2014/1983; First registration: 24/10/2017.https://doi.org/10.1038/s41598-021-01899-8 |
| spellingShingle | Jonatan Olafsson Xiaoran Lai Erlend Christoffer Sommer Landsend Snorri Olafsson Eric Parissi Øygunn A. Utheim Sten Raeder Reza A. Badian Neil Lagali Darlene A. Dartt Tor P. Utheim TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial Scientific Reports |
| title | TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial |
| title_full | TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial |
| title_fullStr | TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial |
| title_full_unstemmed | TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial |
| title_short | TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial |
| title_sort | therapearl eye mask and blephasteam for the treatment of meibomian gland dysfunction a randomized comparative clinical trial |
| url | https://doi.org/10.1038/s41598-021-01899-8 |
| work_keys_str_mv | AT jonatanolafsson therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT xiaoranlai therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT erlendchristoffersommerlandsend therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT snorriolafsson therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT ericparissi therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT øygunnautheim therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT stenraeder therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT rezaabadian therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT neillagali therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT darleneadartt therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial AT torputheim therapearleyemaskandblephasteamforthetreatmentofmeibomianglanddysfunctionarandomizedcomparativeclinicaltrial |